Area of Interest Infectious Disease Infectious Disease with Mass Cytometry

Infectious Disease 

CyTOF technology in the fight against infectious disease 

From SARS-CoV-2 to HIV, malaria, S. Typhi, Ebola and smallpox, mass cytometry is driving understanding of infectious disease and innovation in vaccine development. 

Blue icon illustrating infectious disease application

Uncovering the immunological mechanisms of infection and vaccination 

Investigators working on infectious disease adopted mass cytometry early on because of its ability to identify immune cell populations with breadth and depth simultaneously. The often-limited sample volumes available for clinical research studies mean researchers need to maximize the information gathered from every single cell. 

By quickly and reproducibly profiling 50 or more phenotypic and functional markers in a single tube of sample without requiring extra tubes to account for fluorescence spillover or time-consuming genomic analysis, mass cytometry offers a clear advantage over other single-cell technologies.  

Hundreds of publications attest to the positive impact of CyTOF® on infectious disease research. 

When the SARS-CoV-2 pandemic arrived, the high-dimensional power and data quality of mass cytometry was quickly leveraged by immunologists and consortia around the world to sort out the puzzle of COVID-19 disease and the efficacy of vaccines against the virus and its variants. 

The Maxpar® Direct™ Immune Profiling Assay™: Adoption for use in COVID-19 clinical research  

This dry-format high-parameter mass cytometry panel kit has proven run-to-run and site-to-site reproducibility, is easy to use and can be run with small amounts of either human PBMC or whole blood. The 30-marker backbone panel is expandable, with room to add 14 or more markers. When paired with Maxpar Pathsetter™ software, a detailed analytic report on 37 immune cell populations is ready in 5 minutes or less.  

IMPACC (Immunophenotyping Assessment in a COVID-19 Cohort) Clinical Study (NCT04378777)  

COntAGIous (COVID-19 Advanced Genetic and Immunologic Sampling) Trial (NCT04327570)  

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM) (NCT04588363) 

Find out more about this assay kit and automated data analysis solution. 

Bibliography 

Mass Cytometry in COVID-19 Research 

As of August 2021, over 60 peer-reviewed publications and preprints have been published related to COVID-19 research, and at least 12 National Clinical Trials related to the disease or vaccination trials are employing mass cytometry.  

Webinars 

 

Mass Cytometry in Vaccine Development

Patrick Reeves, PhD 

Instructor in Medicine, Harvard Medical School   Team Leader, Vaccine and Immunotherapy Center Massachusetts General Hospital 

Revealing the Peculiarities of Immune Cells during COVID-19

Andrea Cossarizza, MD, PhD 

Professor of Immunology and Pathology 
University of Modena and Reggio Emilia School of Medicine and Surgery 

Systems-Level Immune Dynamics from Acute to Recovery Phase of Severe COVID-19 

Petter Brodin, MD, PhD

Associate Professor and Consultant Physician 
Science for Life Laboratory, Karolinska Institutet, and Department of Pediatric Rheumatology 
Karolinska University Hospital, Stockholm 

A Complete Immune Monitoring Solution with CyTOF: Ideal for Pandemics and Beyond 

Frederik De Smet, MSc, PhD 

Assistant Professor 
University of Leuven, Belgium 

Find more infectious disease and vaccine development webinars here. 

Publications

Powering over 1,500 scientific publications with our products

VIEW ALL

Marcelo Sztein, MD

Spotlight MC Marcelo

Research focuses on infection, vaccination in humans

Nadia Roan, PhD

UCSF researcher focuses on immune system responses

Lori Turner, PhD

Spotlight MC LORI TURNER

A quick pivot to COVID-19 research with CyTOF

Benjamin Terrier, MD, PhD

Spotlight IMC  BENJAMIN TERRIER

Discovering a hallmark phenotype of COVID-19

customer stories

Learn more about how our customers are leveraging mass cytometry to gain fresh insights.

VIEW ALL

Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only and Not For Use in Diagnostic Procedures. For more information see www.fluidigm.com/legal/notices.